{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:27:28Z","timestamp":1788809248732,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.psychres.2024.115786","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T05:13:25Z","timestamp":1707887605000},"page":"115786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis"],"prefix":"10.1016","volume":"334","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-2339","authenticated-orcid":false,"given":"Diane","family":"Merino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-6966","authenticated-orcid":false,"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-9201","authenticated-orcid":false,"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitam","family":"Saidessalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Askenazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-530X","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-6981","authenticated-orcid":false,"given":"Susanne","family":"Th\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2024.115786_bib0001","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1542\/peds.2011-0855","article-title":"Antipsychotic medication use among children and risk of diabetes mellitus","volume":"128","author":"Andrade","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.psychres.2024.115786_bib0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","article-title":"The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study","volume":"26","author":"Baeza","year":"2017","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0003","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","article-title":"Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure","volume":"2","author":"Bahr","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.psychres.2024.115786_bib0004","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-019-1346-1","article-title":"The effects of antipsychotic medications on microbiome and weight gain in children and adolescents","volume":"17","author":"Bretler","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.psychres.2024.115786_bib0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/cap.2020.0173","article-title":"Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education","volume":"31","author":"Bussell","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0006","unstructured":"Centre, U.M., n.d. VigiBase: WHO's global database signalling harm and pointing to safer use [WWW.Document]. URL https:\/\/who-umc.org\/vigibase\/vigibase-who-s-global-database\/(accessed 2.2.24)."},{"key":"10.1016\/j.psychres.2024.115786_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2478\/jccm-2020-0035","article-title":"Cardiopulmonary Arrest Following a Single 25 Mg Dose of Quetiapine: A Case Report","volume":"6","author":"Chia","year":"2020","journal-title":"J. Crit. Care Med. (Targu Mures)"},{"key":"10.1016\/j.psychres.2024.115786_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","article-title":"Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis","volume":"32","author":"Cohen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0706743717751693","article-title":"Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics","volume":"63","author":"Coughlin","year":"2018","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/cap.2020.0014","article-title":"Aripiprazole in Children and Adolescents","volume":"31","author":"Coustals","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0011","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2024.115786_bib0012","unstructured":"EMA, 2018. EMA: Leponex (clozapine) [WWW.Document]. European Medicines Agency. URL https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/leponex (accessed 4.11.22)."},{"key":"10.1016\/j.psychres.2024.115786_bib0014","unstructured":"EMA, 2018a. Zyprexa [WWW.Document]. European Medicines Agency. URL https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zyprexa (accessed 4.15.22)."},{"key":"10.1016\/j.psychres.2024.115786_bib0015","unstructured":"FDA, n.d. Drugs@FDA: Risperdal - New Patient Population [WWW.Document]. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020272 (accessed 5.30.23)."},{"key":"10.1016\/j.psychres.2024.115786_bib0016","unstructured":"FDA-Approved Drugs : Clozapine [WWW.Document], n.d. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=019758 (accessed 4.11.22a)."},{"key":"10.1016\/j.psychres.2024.115786_bib0017","unstructured":"FDA-Approved Drugs : Olanzapine [WWW.Document], n.d. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020592 (accessed 4.11.22b)."},{"key":"10.1016\/j.psychres.2024.115786_bib0018","unstructured":"FDA-Approved Drugs: Seroquel [WWW.Document], n.d. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020639 (accessed 9.17.22c)."},{"key":"10.1016\/j.psychres.2024.115786_bib0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0020","first-page":"316","article-title":"Characterization of Serious Adverse Drug Reactions in Hospital to Determine Potential Implications of Mandatory Reporting","volume":"71","author":"Gautron","year":"2018","journal-title":"Can. J. Hosp. Pharm."},{"key":"10.1016\/j.psychres.2024.115786_bib0021","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/20473869.2019.1638583","article-title":"Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments","volume":"67","author":"Goltz","year":"2019","journal-title":"Int. J. Dev. Disabil."},{"key":"10.1016\/j.psychres.2024.115786_bib0022","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2024.115786_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/cap.2018.0167","article-title":"Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities","volume":"29","author":"Javaheri","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0024","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/0706743720974847","volume":"66","author":"Jazi","year":"2021","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jaac.2019.01.015","volume":"58","author":"Jensen","year":"2019","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40264-022-01252-6","article-title":"Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase\u00ae","volume":"46","author":"Kaguelidou","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2024.115786_bib0027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/15622970310029911","article-title":"Broadening the treatment indication: is the term antipsychotic still justified?","volume":"4","author":"Kasper","year":"2003","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children","volume":"12","author":"Libowitz","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0029","first-page":"409","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.psychres.2024.115786_bib0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11606-017-4205-9","article-title":"Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study","volume":"33","author":"Mangurian","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.psychres.2024.115786_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/cap.2020.0093","article-title":"CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review","volume":"31","author":"Maruf","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0032","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/00048674211009620","article-title":"Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: A systematic review","volume":"55","author":"Mead","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0033","unstructured":"MedDRA, n.d. MedDRA Hierarchy | MedDRA [WWW Document]. URL https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy (accessed 9.3.21)."},{"key":"10.1016\/j.psychres.2024.115786_bib0034","article-title":"Emergence of psychiatric adverse events during antipsychotic treatment in AP-na\u00efive children and adolescents","author":"Menard","year":"2022","journal-title":"Child and Adolescent Psychiatry and Mental Health Accepted"},{"key":"10.1016\/j.psychres.2024.115786_bib0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/ph15060749","article-title":"Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review","volume":"15","author":"Merino","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.psychres.2024.115786_bib0036","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/biomedicines10112972","article-title":"Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis","volume":"10","author":"Merino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.psychres.2024.115786_bib0037","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01404-1","article-title":"The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans","author":"Merino","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.psychres.2024.115786_bib0038","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","article-title":"Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case","volume":"33","author":"Meyer-Massetti","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.psychres.2024.115786_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2021.12.010","article-title":"Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA","author":"Mofid","year":"2022","journal-title":"Clin. Ther."},{"key":"10.1016\/j.psychres.2024.115786_bib0040","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00213-016-4422-7","article-title":"Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study","volume":"233","author":"Morl\u00e1n-Coarasa","year":"2016","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.psychres.2024.115786_bib0041","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.chi.0000157543.74509.c8","article-title":"Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents","volume":"44","author":"Patel","year":"2005","journal-title":"J. Am. Acad. Child Adoles. Psych."},{"key":"10.1016\/j.psychres.2024.115786_bib0042","doi-asserted-by":"crossref","unstructured":"Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J., 2011. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth 16, 9.","DOI":"10.1093\/pch\/16.9.581"},{"key":"10.1016\/j.psychres.2024.115786_bib0043","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"key":"10.1016\/j.psychres.2024.115786_bib0044","unstructured":"SFPEADA, n.d. Troubles psychotiques | Site de pharmacologie [WWW Document]. URL https:\/\/pharmacologie.sfpeada.fr\/trouble\/5\/7 (accessed 1.24.23)."},{"key":"10.1016\/j.psychres.2024.115786_bib0045","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in off-label use of atypical antipsychotics in children and adolescents in the United States","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.psychres.2024.115786_bib0046","doi-asserted-by":"crossref","first-page":"173","DOI":"10.14712\/fb2013059050173","article-title":"Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study)","volume":"59","author":"Soliman","year":"2013","journal-title":"Folia Biol. (Praha)"},{"key":"10.1016\/j.psychres.2024.115786_bib0047","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database","volume":"14","author":"Subeesh","year":"2019","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.psychres.2024.115786_bib0048","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.psychres.2024.115786_bib0049","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1192\/bjp.2019.20","article-title":"Dietary intake of people with severe mental illness: systematic review and meta-analysis","volume":"214","author":"Teasdale","year":"2019","journal-title":"Br. J. Psychiat."},{"key":"10.1016\/j.psychres.2024.115786_bib0050","unstructured":"Uppsala Monitoring Centre, n.d. About VigiBase [WWW Document]. URL https:\/\/who-umc.org\/vigibase\/(accessed 9.26.22)."},{"key":"10.1016\/j.psychres.2024.115786_bib0051","unstructured":"Uppsala Reports - Record growth pushes VigiBase past 28 million reports [WWW Document], n.d. URL https:\/\/www.uppsalareports.org\/articles\/record-growth-pushes-vigibase-past-28-million-reports\/(accessed 1.29.24)."},{"key":"10.1016\/j.psychres.2024.115786_bib0052","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1089\/cap.2016.0090","article-title":"No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder","volume":"26","author":"Vo","year":"2016","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.115786_bib0053","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","article-title":"Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre","volume":"41","author":"Watson","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2024.115786_bib0054","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/clpt.2014.139","article-title":"Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest","volume":"96","author":"Weeke","year":"2014","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.psychres.2024.115786_bib0055","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004583-200212000-00015","article-title":"Effects of development on olanzapine-associated adverse events","volume":"41","author":"Woods","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2024.115786_bib0056","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr. Bull."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178124000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178124000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:38:39Z","timestamp":1731310719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178124000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"alternative-id":["S0165178124000714"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2024.115786","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2024.115786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115786"}}